Tremeau Pharmaceuticals is focused on developing innovative non-opioid pain therapies aimed at addressing the needs of patient populations with significant unmet medical requirements. The company emphasizes a unique approach to managing both acute and chronic pain through the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs). Their investigational products, TRM-201 and TRM-362, leverage the mechanisms of action and efficacy profiles of previously established compounds, such as rofecoxib and etoricoxib, respectively. Tremeau's strategy includes a thorough re-evaluation of these compounds, particularly in contexts where they may offer therapeutic advantages over traditional opioid treatments.

TRM-201, which contains rofecoxib, is designed to provide effective pain relief while minimizing gastrointestinal risks, as it has been shown to have no effect on bleeding time and a reduced risk of gastrointestinal bleeding compared to traditional NSAIDs. Meanwhile, TRM-362 utilizes deuterated etoricoxib, which has demonstrated superior efficacy and tolerability compared to opioids in certain acute pain scenarios. The deuteration process may enhance the metabolic profile of the drug while preserving its pharmacodynamic properties. Both investigational therapies are protected by U.S. patents, ensuring their proprietary status as Tremeau continues to advance its mission of delivering effective non-opioid pain management solutions.

United States

Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs.

Tremeau’s unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs. 

Tremeau Pharmaceuticals

Company Details